Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Lantheus
LNTH
5
Cars.com
CARS
US OptionsDetailed Quotes
TRML250516P17500
- 1.69
- 0.000.00%
15min DelayClose May 1 16:00 ET
0.00High0.00Low
1.69Open1.69Pre Close0 Volume1 Open Interest17.50Strike Price0.00Turnover133.99%IV11.43%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry1.69Extrinsic Value100Contract SizeAmericanOptions Type-0.4156Delta0.0820Gamma10.56Leverage Ratio-0.0644Theta-0.0033Rho-4.39Eff Leverage0.0138Vega
Tourmaline Bio Newsroom
Cantor Fitzgerald Maintains Tourmaline Bio(TRML.US) With Buy Rating
Chardan Capital Initiates Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $70
Tourmaline Bio Initiated at Buy by Chardan Capital
Tourmaline Bio Price Target Announced at $70.00/Share by Chardan Capital
Jefferies Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $64
Companies Like Tourmaline Bio (NASDAQ:TRML) Are In A Position To Invest In Growth
Here's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Situation
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $63
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $63
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and Tourmaline Bio (TRML)
Truist Cuts Price Target on Tourmaline Bio to $63 From $74, Keeps Buy Rating
BMO Capital Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $50
Tourmaline Bio's TOUR006: Potential Best-in-Class IL-6 Treatment With Strategic Market Positioning
New Analyst Forecast: $TRML Given $50.0 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Wedbush Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $43
Tourmaline Bio Price Target Raised to $43.00/Share From $42.00 by Wedbush
Tourmaline Bio Is Maintained at Outperform by Wedbush
Truist Financial Sticks to Their Buy Rating for Tourmaline Bio (TRML)
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now